Shared Decision Making in Hospitalized AECOPD

COPD Exacerbation Clinical Trial

Official title:

Shared Decision Making and Patient Engagement Program During AECOPD Hospitalization

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03772639
• Other study ID #: DF0082UG
• Status: Completed
• Phase: N/A
• Start date: October 2016
• Est. completion date: January 2019

Study information

• Verified date: February 2020
• Source: Universidad de Granada
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Patients require good communication with the physician to improve control illness. Shared decision making is a promising opportunity for chronic disease management due to the relative cost, medicine optimization and decreases hospital admissions/re-admissions

Description:

Chronic obstructive pulmonary disease (COPD) is the leading one on hospital care cost, physician services, and prescription drugs. Additionally to the disease progression with the reduction in lung function, COPD patients experiment a progressive decline in functional capacity and health-related quality of life (HRQoL) with a significant burden in terms of disability. Shared Decision Making is defined as an approach where clinicians and patients share the available information to making clinical decisions, and where patients are counseled. SDM is a way to empower patients when decisions are made about treatment as a determinant factor in patient-centered care. Decision aids have been proven effective in improving disease knowledge, decision making, and self-care.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: January 2019
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Inclusion criteria were COPD patients hospitalized due to acute exacerbation

Exclusion Criteria:

• Exclusion criteria were the inability to provide informed consent, the presence of psychiatric or cognitive disorders, progressive neurological disorders, organ failure, cancer, or inability to cooperate. Patients who had experienced another exacerbation of COPD in the previous month were also excluded.

Related Conditions & MeSH terms

• COPD Exacerbation

Intervention

Other:
• Shared decision making
Decision-making processes focused on the knowledge of the disease for set up adjusted care management about their necessities and engaging in recommended health behaviors

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Universidad de Granada

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Health related quality of life	European Quality of Life questionnaire consists of the EQ-5D visual analog scale and the EQ-5D index. The visual analog scale has a rating scale of 0-100 (0 worst possible health, and 100 best possible health). The questionnaire has 5 domains: mobility, self-care, usual activity, pain, and anxiety-depression. For each item, the subject selects one of 3 descriptive health states (from good to poor).	Participants will be followed for the duration of hospital stay, an expected average of 9 days and after discharge 3 months follow up
Secondary	COPD Knowledge	Chronic Obstructive Pulmonary Disease Questionnaire (COPD-Q). COPD knowledge was evaluated using the Chronic Obstructive Pulmonary Disease Knowledge Questionnaire (COPD-Q; Maples, Franks, Ray, Stevens, & Wallace, 2010). The COPD-Q is a valid, readable, and reliable 13-item (each one score 0 to 3) self-administered true/false questionnaire assessing COPD knowledge in patients with low health literacy skills. A higher punctuation indicates better results.	Participants will be followed for the duration of hospital stay, an expected average of 9 days and after discharge 3 months follow up
Secondary	Adherence of inhalers	The Test of Adherence to Inhalers (TAI) was used to assess the level of adherence to inhalers in asthma and COPD patients. The test has two subscores, first to identify non-adherent patients and to measure the non-adherence level, second was designed to guide clinically the treatment non-compliance patients. Low adherence is considered when scores are less than 45 points in the 10-items subscore.	Participants will be followed for the duration of hospital stay, an expected average of 9 days and after discharge 3 months follow up
Secondary	Functional capacity	Functional independence was assessed using the Functional Independence Mease Scale (FIM). This scale has 18 items that are grouped into 2 dimensions, 13 motor items, and 5 cognitive items. The total score range between 18 points (total dependence) to 126 points (Independence completes).	Participants will be followed for the duration of hospital stay, an expected average of 9 days and after discharge 3 months follow up
Secondary	Physical activity	The International Physical Activity Questionnaire (IPAQ) short form measures walking, moderate- and vigorous intensity, and total PA and daily time spent sitting on weekdays. PA was reported in MET·minutes/week and days per week and was scored using standardized IPAQ scoring protocols to yield total metabolic equivalent minutes (MET·minutes/week) of PA per week. Sitting time was reported as the amount of time in hours and/or minutes participants spent sitting on a weekday during the past seven days.	Participants will be followed for the duration of hospital stay, an expected average of 9 days and after discharge 3 months follow up
Secondary	Nutritional status	Nutritional status was assessed with Mini Nutritional Assessment (MNA). The MNA has a screening- and assessment part. The screening part consists of questions about food intake, weight loss, mobility, stress, neuropsychological problems and weight and height will be combined to report BMI in kg/m^2. When the MNA punctuation is = 24 nutritional status can be considered good.	Participants will be followed for the duration of hospital stay, an expected average of 9 days and after discharge 3 months follow up
Secondary	Functional capacity associated with breathlessness	Functional capacity associated with breathlessness was assessed with London Chest Activity of Daily Living Scale (LCADL): The LCADL is a 15-item scale divided into 4 domains: self-care (4 items), domestic (6 items), physical (2 items), and leisure (3 items). The use of 0 representing `I wouldn't do any way' and 5 representing that patients require help.	Participants will be followed for the duration of hospital stay, an expected average of 9 days and after discharge 3 months follow up